Bone Biologics files NELL-1 protein patent application with USPTO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 27 2025
0mins
Patent Application Filed: Bone Biologics has filed a patent application with the United States Patent and Trademark Office for its innovative NELL-1 protein.
Therapeutic Uses: The patent focuses on compositions of rhNELL-1 polypeptide and its applications in treating various bone conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBLG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBLG
About BBLG
Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bone Biologics Extends rhNELL-1 Product Shelf Life to 24 Months
- Product Shelf Life Extension: Bone Biologics successfully extended the shelf life of its rhNELL-1 protein product to 24 months, which not only enhances manufacturing efficiency but also improves supply chain flexibility, supporting clinical readiness.
- Strengthened Capital Structure: The company completed a $5 million registered public offering in Q2 2025, providing funding to support ongoing clinical development activities and intellectual property initiatives, ensuring stability in capital markets.
- Intellectual Property Expansion: Bone Biologics filed a U.S. patent application related to its bone regeneration technology, further strengthening its proprietary platform and enhancing long-term value in the competitive landscape.
- Nasdaq Compliance Restored: The company regained compliance with Nasdaq's minimum bid price requirement in June 2025, reinforcing its ability to access public capital markets continuously.
Continue Reading
Bone Biologics Extends rhNELL-1 Product Shelf Life to 24 Months
- Shelf Life Extension: Bone Biologics announces that the shelf life of its rhNELL-1 product has been extended to 24 months, based on ongoing stability data, representing a logical progression from prior 12- and 18-month milestones.
- Manufacturing Efficiency Improvement: The extended shelf life is expected to enhance manufacturing efficiency, inventory management, and supply chain flexibility, thereby supporting clinical and commercial readiness as the company advances product development.
- Accelerated Commercialization: CEO Jeff Frelick states that this milestone is an important step toward commercialization, expected to support disciplined capital deployment and long-term shareholder value creation.
- Bone Regeneration Technology Development: Bone Biologics is developing rhNELL-1 as a differentiated bone growth factor designed to promote bone regeneration in hard-to-heal fusion settings, further solidifying its competitive position in the spinal fusion market.
Continue Reading